Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese

BMC Cancer

Table 4 Sensitivity analyses estimating hazard ratios for non-melanoma skin cancer associated with rosiglitazone exposure

Rosiglitazone use	Setting entry date to 1 January 2005			Deleting patients who developed skin cancer within 3 months of follow-up			Excluding patients with a history of any cancer before 2006			Including pioglitazone users in the analyses			Time-dependent models
Rosiglitazone use	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Ever users	0.986	(0.882, 1.102)	0.7977	0.933	(0.809, 1.075)	0.3368	0.951	(0.834, 1.083)	0.4469	0.938	(0.835, 1.055)	0.2863	0.909	(0.785, 1.051)	0.1981
Duration of therapy (months)
<3.73	1.177	(0.975, 1.421)	0.0903	1.119	(0.900, 1.392)	0.3106	1.055	(0.855, 1.302)	0.6199	1.114	(0.930, 1.336)	0.2411	1.287	(1.050, 1.579)	0.0153
3.73-13.77	1.112	(0.939, 1.318)	0.2189	0.989	(0.792, 1.234)	0.9194	1.096	(0.906, 1.325)	0.3452	1.025	(0.862, 1.219)	0.7781	1.059	(0.851, 1.317)	0.6099
>13.77	0.787	(0.662, 0.935)	0.0065	0.713	(0.554, 0.918)	0.0087	0.737	(0.592, 0.916)	0.0060	0.718	(0.589, 0.874)	0.0010	0.583	(0.457, 0.740)	<0.0001
P-trend			0.1215			0.0484			0.0871			0.0186			0.0024
Cumulative dose (mg)
<448	1.138	(0.939, 1.379)	0.1883	1.092	(0.876, 1.361)	0.4336	0.985	(0.793, 1.223)	0.8882	1.059	(0.880, 1.275)	0.5418	1.286	(1.030, 1.607)	0.0264
448-1752	1.099	(0.929, 1.301)	0.2722	0.923	(0.735, 1.159)	0.4892	1.105	(0.915, 1.334)	0.3015	1.011	(0.849, 1.203)	0.9047	0.983	(0.775, 1.247)	0.8876
>1752	0.815	(0.687, 0.966)	0.0186	0.798	(0.627, 1.016)	0.0672	0.780	(0.630, 0.965)	0.0224	0.773	(0.638, 0.936)	0.0084	0.614	(0.476, 0.792)	0.0002
P-trend			0.1839			0.0971			0.1685			0.0482			0.0041

Referent group: never-users of rosiglitazone; HR: hazard ratio, CI: confidence intervals.
In models excluding patients not treated with rosiglitazone and using the first tertile of exposure as referent, the hazard ratio (95% confidence interval) for the second and third tertile of duration of therapy was 0.850 (0.634, 1.140) (P = 0.2777) and 0.639 (0.465, 0.876) (P = 0.0054), respectively (P-trend = 0.0054); and was 0.852 (0.633, 1.148) and 0.712 (0.521, 0.973), respectively, for cumulative dose (P-trend = 0.0327).

ISSN: 1471-2407